Key takeaways
Rybelsus (semaglutide) and Adipex-P (phentermine) are both medications that can help people lose weight, but they belong to different medication classes and have distinct uses. Rybelsus is a glucagon-like peptide-1 (GLP-1) receptor agonist primarily FDA-approved for treating Type 2 diabetes, with weight loss being a potential off-label benefit. In contrast, Adipex-P is a sympathomimetic stimulant specifically FDA-approved for short-term weight management in adults with a high body mass index (BMI). Rybelsus is taken as an oral tablet once daily, while Adipex-P is also taken orally but can be dosed once or twice daily depending on the form. Rybelsus is only available as a brand-name medication, whereas Adipex-P is available as a lower-cost generic. Common side effects of Rybelsus include nausea, vomiting, and diarrhea, while Adipex-P may cause dry mouth and trouble sleeping. Rybelsus has a warning for thyroid cancer, and Adipex-P is a controlled substance and carries a risk of misuse and dependence. Additionally, Rybelsus can interact with other diabetes medications, and Adipex-P should not be combined with other weight loss medications.
